CHINAPLAS
12.3.2019 03:02:11 CET | Business Wire | Press release
The operating environment for most industries became increasingly complex. It is more vital than ever for enterprising businesses to master technological innovation. CHINAPLAS , the Asia’s No. 1 plastics and rubber trade fair, offers an international platform for the release and exchange of advanced new technologies. The show will not only feature more than 3,500 exhibitors but will also organize a series of exciting concurrent events to address those industries’ needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190311005047/en/
Plastics Recycling & Circular Economy Conference and Showcase
To foster circular economy is a global consensus to achieve sustainable development. Great potential and bounteous market opportunities arise with it. More and more big brands have announced environmental protection policies of recycling. In 2017, Adidas sold 1 million pairs of running shoes made of ocean plastic waste. How can plastics contribute to sustainable development? Focusing on the concerns of the industry, a “Plastics Recycling & Circular Economy Conference and Showcase ”, will be held with the themes of “Material Science for Sustainability”, “Recycling Technology” and “Environmental Packaging”.
Industry 4.0 Factory of the Future
Industry practitioners can visit the “Industry 4.0 Factory of the Future ” at CHINAPLAS 2019. There will be two themed areas, “Manufacturing Intelligence Control Room” and “Smart Factory”, to demonstrate implementable intelligent solutions. The control room will display operational data recorded at both the on-site machines and a remote smart factory, while the “Smart Factory” will simulate the future manufacturing environment.
Design x Innovation
Recognizing the key role of design in product development, CHINAPLAS 2019 will organize the event “Design x Innovation ”, comprising three parts.
1. CMF Inspiration Walls will display rich resources on Color, Material and Finish.
2. Design Forum will share product experience covering recyclable & sustainable design, low carbon design and CMF applications.
3. CHINAPLAS Designers’ Night .
Tech Talk
By way of open forums, “Tech Talk ” will showcase the hottest product technologies, and focus clearly on cutting-edge solutions. Tech Talk will include 11 major themes, including new energy vehicles, automotive thermoplastic elastomers, 3D printing, Bioplastics, composites, antimicrobial applications, in-mold labeling, precision extrusion, green building solutions, plastics for wearable electronics, long fiber injection molding.
Medical Plastics Connect
“Medical Plastics Connect ” actively promotes medical-grade chemical raw materials and equipment to create an efficient communication platform for medical device, consumables, and pharmaceutical packaging manufacturers. These activities aim to pinpoint for potential buyers the unique medical plastics technologies among the many exhibits active in this sector. "Medical Plastics Connect” activities include “Open Forum”, “Pop-up Kiosk”, “Medical Plastics Guidebook” and “Medical Plastics Guided Tour”.
CHINAPLAS , the Asia’s No. 1 plastics and rubber trade fair, will be held in Guangzhou, PR China, from May 21-24, 2019. An estimated total of over 3,500 exhibitors from all over the world will be presenting to more than 180,000 professional visitors from 150 countries and regions. For more information and pre-registration, please click here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190311005047/en/
Contact:
Stella Yuen Chinaplas.PR@adsale.com.hk
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom